With so many weight loss medications on the market, it's easy to feel overwhelmed by the options. From brand-name heavy ...

More than half of Americans qualify for GLP-1 receptor agonist drugs, but many can't afford them. Experts share cheaper ...

Patients lost an average of 20.2% of their weight with tirzepatide over 72 weeks versus 13.7% with semaglutide.

Despite the ubiquitousness of injectable GLP-1 drugs indicated for people with obesity ... to rate their level of agreement ...

Ozempic and other GLP-1 agonist medications have risen in popularity over the last few years due to their touted blood sugar management and weight-loss effects. However, some supp ...

Randomised controlled trials and real word evidence have consistently shown that GLP-1 receptor agonists are effective and ...

Kara Kennedy's husband was a yo-yo dieter for decades, until he discovered Zepbound – an Ozempic-like drug – and lost 3.5 ...

Jeffrey Segal MD, JD, a medico-legal expert and the founder of Medical Justice, discussed the shifting dynamics of the market for GLP-1 receptor agonist medications in a recent blog, “The Whirlwind ...

Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.

Amylin analogs present a strong alternative or complement to GLP-1 receptor agonists, potentially eliciting higher-quality ...

RealSelf, the largest and most trusted online resource for people exploring cosmetic treatments and providers, today revealed ...